Boston Therapeutics, Inc. | Business Contracts

Description of Securities of Nanomix Corporation (Filed With SEC on April 7, 2023)

Offer Letter for Chris Hetterly, dated November 15, 2022 (Filed With SEC on January 25, 2023)

Subscription Agreement, dated October 21, 2022, by and between the Company and the Investor (Filed With SEC on November 10, 2022)

Offer Letter, dated July 21, 2022 (Filed With SEC on July 29, 2022)

Form of Warrant assumed as part of the Nanomix Merger (Filed With SEC on July 6, 2022)

Offer Letter, dated February 28, 2022 (Filed With SEC on May 10, 2022)

Description of Securities of Nanomix Corporation (Filed With SEC on April 12, 2022)

Development and License Agreement, dated September 26, 2017 by and between RedPharm (Beijing) Biotechnology Co., Ltd. and Medical Technology Associates II, Inc. and Nanomix, Inc (Filed With SEC on April 12, 2022)

First Amendment to Development and License Agreement, dated September 1, 2018 by and between RedPharm (Beijing) Biotechnology Co., Ltd. and Medical Technology Associates II, Inc.... (Filed With SEC on April 12, 2022)

Form of Warrant, dated March 23, 2022 (Filed With SEC on March 24, 2022)

Securities Purchase Agreement, dated March 23, 2022 (Filed With SEC on March 24, 2022)

Consent, Amendment and Waiver, dated March 22, 2022 (Filed With SEC on March 24, 2022)

Form of Senior Secured Convertible Note, dated February 28, 2022 (Filed With SEC on March 1, 2022)

Form of Warrant, dated February 28, 2022 (Filed With SEC on March 1, 2022)

Securities Purchase Agreement, dated February 28, 2022 (Filed With SEC on March 1, 2022)

Consent, Amendment and Waiver, dated February 24, 2022 (Filed With SEC on March 1, 2022)

Form of Senior Secured Convertible Note, dated June 25, 2021 (Filed With SEC on June 29, 2021)

Form of Warrant, dated June 25, 2021 (Filed With SEC on June 29, 2021)

Securities Purchase Agreement, dated June 25, 2021, by and between Boston Therapeutics, Inc. and the buyers signatory thereto (Filed With SEC on June 29, 2021)

Registration Rights Agreement, dated June 25, 2021, by and between Boston Therapeutics, Inc. and the buyers signatory thereto (Filed With SEC on June 29, 2021)

Security and Pledge Agreement, dated June 25, 2021, by and between Boston Therapeutics, Inc, each of the Companys subsidiaries and HT Investments MA LLC, in its capacity as... (Filed With SEC on June 29, 2021)

Guaranty, dated June 25, 2021, by each of the Companys subsidiaries in favor of HT Investments MA LLC, in its capacity as collateral agent (Filed With SEC on June 29, 2021)

Form of Exchange Agreement, dated June 25, 2021, with existing holders of convertible promissory notes (Filed With SEC on June 29, 2021)

Form of Promissory Note dated April 30, 2021 (Filed With SEC on May 12, 2021)

Form of 10% Promissory Note issued by Nanomix, Inc. to Boston Therapeutics Inc (Filed With SEC on May 12, 2021)

Agreement and Plan of Merger, dated February 2, 2021, by and between Boston Therapeutics, Inc.., BTHE Acquisition Inc. and Nanomix, Inc (Filed With SEC on February 2, 2021)

Certificate of Designation Series B Preferred Stock (Filed With SEC on February 2, 2021)

Form of Exchange Agreement (Filed With SEC on February 2, 2021)

Form of Debt Settlement and Release Agreement (Filed With SEC on February 2, 2021)

Unwind Agreement between Boston Therapeutics, Inc., Cure DM, Inc. and Cure DM Group Holdings, LLC signed August 6, 2019 (Filed With SEC on August 19, 2019)

License Agreement between Boston Therapeutics, Inc. and Level Brands, Inc. dated June 26, 2018 (Filed With SEC on July 2, 2018)

Form of Promissory Note dated June 12, 2018 (Filed With SEC on June 14, 2018)

Form of Contribution Agreement between Boston Therapeutics, Inc., CureDM Group, LLC and the members of CureDM Group Holdings, LLC dated January 1, 2018 (Filed With SEC on February 12, 2018)

Executive Retention Agreement between Boston Therapeutics, Inc. and Loraine Upham (Filed With SEC on February 12, 2018)

Form of Securities Purchase Agreement entered between Boston Therapeutics, Inc. dated August 14, 2017 (Filed With SEC on August 22, 2017)

Certificate of Designation dated August 14, 2017 (Filed With SEC on August 22, 2017)

Form of Common Stock Purchase Warrant issued to the Investors (Filed With SEC on August 22, 2017)

Securities Purchase Agreement entered between Boston Therapeutics, Inc. and CJY Holdings Limited (Filed With SEC on May 2, 2017)

Form of 6% Subordinated Convertible Debenture (Filed With SEC on May 2, 2017)

Form of Stock Purchase Warrants (Filed With SEC on May 2, 2017)

Letter Agreement dated March 27, 2017 entered between Boston Therapeutics, Inc. and Carl W. Rausch (Filed With SEC on March 28, 2017)

Form of Securities Purchase Agreement entered with the August 2016 Accredited Investors (Filed With SEC on August 15, 2016)

Form of 6% Senior Convertible Debuenture (Filed With SEC on August 15, 2016)

Form of Stock Purchase Warrant (Filed With SEC on August 15, 2016)

Letter Agreement between the Company and CJY Holdings Limited dated August 12, 2016 (Filed With SEC on August 15, 2016)

Executive Employment Agreement between the Company and Carl. W. Rausch dated August 12, 2016 (Filed With SEC on August 15, 2016)

Letter Amendment by and between Boston Therapeutics, Inc. and CJY Holdings Limited dated June 28, 2016 (Filed With SEC on July 6, 2016)

Letter Amendment by and between Boston Therapeutics, Inc. and CJY Holdings Limited dated May 6, 2016 (Filed With SEC on May 12, 2016)

Letter Amendment by and between Boston Therapeutics, Inc. and CJY Holdings Limited dated March 11, 2016 (Filed With SEC on March 22, 2016)

Letter Amendment by and between Boston Therapeutics, Inc. and CJY Holdings Limited dated March 1, 2016 (Filed With SEC on March 2, 2016)

Letter Amendment by and between Boston Therapeutics, Inc. and CJY Holdings Limited dated November 30, 2015 (Filed With SEC on December 10, 2015)

Warrant Repricing and Exercise Agreement entered by and between Boston Therapeutics, Inc. and CJY Holdings Limited dated November 12, 2015, effective June 15, 2015 (Filed With SEC on November 12, 2015)

Letter Amendment by and between Boston Therapeutics, Inc. and CJY Holdings Limited (Filed With SEC on October 30, 2015)

Form of Securities Purchase Agreement by and between Boston Therapeutics, Inc. and CJY Holdings Limited (Filed With SEC on October 2, 2015)

Form of 10% Convertible Promissory Note issued to CJY Holdings Limited (Filed With SEC on October 2, 2015)

Letter Agreement by and between Boston Therapeutics, Inc. and Typenex Co-Investment, LLC (Filed With SEC on October 2, 2015)

Securities Purchase Agreement between Boston Therapeutics, Inc. and JDF Capital, Inc. dated as of March 13, 2015 (Filed With SEC on May 20, 2015)

Convertible Promissory Note between Boston Therapeutics, Inc. and JDF Capital, Inc. dated as of March 13, 2015 (Filed With SEC on May 20, 2015)

Convertible Note between Boston Therapeutics, Inc. and JMJ Financial dated as of March 18, 2015 (Filed With SEC on May 20, 2015)

Securities Purchase Agreement between Boston Therapeutics, Inc. and Vis Vires Group, Inc. dated as of March 16, 2015 (Filed With SEC on May 20, 2015)

Convertible Promissory Note between Boston Therapeutics, Inc. and Vis Vires Group, Inc. dated as of March 16, 2015 (Filed With SEC on May 20, 2015)

Securities Purchase Agreement between Boston Therapeutics, Inc. and Typenex Co-Investment, LLC dated as of March 12, 2015 (Filed With SEC on May 20, 2015)

Convertible Promissory Note between Boston Therapeutics, Inc. and Typenex Co-Investment, LLC dated as of March 12, 2015 (Filed With SEC on May 20, 2015)

Warrant to Purchase Shares of Common Stock between Boston Therapeutics, Inc. and Typenex Co-Investment, LLC dated as of March 12, 2015 (Filed With SEC on May 20, 2015)

Form of Warrant issued to investors in this offering (Filed With SEC on April 28, 2015)

Form of Subscription Agreement (Filed With SEC on April 28, 2015)

Marketing Agreement between Boston Therapeutics, Inc. Benchworks SD LLC dated as of May 14, 2014 (Filed With SEC on November 7, 2014)

Separation Agreement and General Release between Boston Therapeutics, Inc. and Kenneth A. Tassey, Jr., effective June 30, 2014 (Filed With SEC on August 8, 2014)

COMMON STOCK PURCHASE WARRANT BOSTON THERAPEUTICS, INC. (Filed With SEC on March 14, 2014)

Form of Investor Warrant (Filed With SEC on November 14, 2013)

Form of Placement Agent Warrant (Filed With SEC on November 14, 2013)

Technology Assignment Agreement dated as of August 24, 2009 by and between the Company and David Platt (Filed With SEC on November 14, 2013)

Boston Therapeutics, Inc. Amended and Restated 2010 Stock Plan (Filed With SEC on November 14, 2013)

Boston Therapeutics, Inc. 2011 Non-Qualified Stock Plan (Filed With SEC on November 14, 2013)

Promissory Note dated as of February 9, 2010 issued by the Company to David Platt (Filed With SEC on November 14, 2013)

Agreement and Plan of Merger dated November 10, 2010 by and among Avanyx Therapeutics, Inc. and Boston Therapeutics, Inc (Filed With SEC on November 14, 2013)

Certificate of Merger (Filed With SEC on November 14, 2013)

Form of Subscription Agreement dated June 21, 2011, among Boston Therapeutics, Inc. and the Investors named therein (Filed With SEC on November 14, 2013)

License and Manufacturing Agreement between Boston Therapeutics, Inc. and Advance Pharmaceutical Company Limited effective as of June 24, 2011 (Filed With SEC on November 14, 2013)

Employment Agreement between Boston Therapeutics, Inc. and Ken Tassey dated as of August 11, 2011 (Filed With SEC on November 14, 2013)

Unit Purchase Agreement between Boston Therapeutics, Inc. and the investors named therein dated as of July 23, 2013, as amended (Filed With SEC on November 14, 2013)

Registration Rights Agreement between Boston Therapeutics, Inc. and the investors named therein dated as of July 23, 2013, as amended (Filed With SEC on November 14, 2013)

Form of Investor Warrant (Filed With SEC on November 13, 2013)

Form of Private Placement Warrant (Filed With SEC on November 13, 2013)

Boston Therapeutics, Inc. Amended and Restated 2010 Stock Plan (Filed With SEC on November 13, 2013)

Unit Purchase Agreement between Boston Therapeutics, Inc. and the investors named therein dated as of July 23, 2013, as amended (Filed With SEC on November 13, 2013)

Registration Rights Agreement between Boston Therapeutics, Inc. and the investors named therein dated as of July 23, 2013, as amended (Filed With SEC on November 13, 2013)

Amended and Restated 2010 Stock Plan (Filed With SEC on June 6, 2013)

Boston Therapeutics, Inc. OTCQB:BTHE1750 Elm Street Suite 103Manchester, NH03104Tel: (603) 935-9799Fax: (603) 685-4784www.bostonti.com (Filed With SEC on November 13, 2012)

Specimen Warrant (Filed With SEC on October 5, 2012)

Technology Assignment Agreement dated as of August 24, 2009 by and between the Company and David Platt (Filed With SEC on September 21, 2012)

Avanyx Therapeutics, Inc. 2010 Stock Plan (Filed With SEC on September 21, 2012)

Boston Therapeutics, Inc. 2011 Non-Qualified Stock Plan (Filed With SEC on September 21, 2012)

Promissory Note dated as of February 9, 2010 issued by the Company to David Platt (Filed With SEC on September 21, 2012)

Agreement and Plan of Merger dated November 10, 2010 by and among Avanyx Therapeutics, Inc. and Boston Therapeutics, Inc (Filed With SEC on September 21, 2012)

Certificate of Merger (Filed With SEC on September 21, 2012)

Form of Subscription Agreement dated June 21, 2011, among Boston Therapeutics, Inc. and the Investors named therein (Filed With SEC on September 21, 2012)

License and Manufacturing Agreement between Boston Therapeutics, Inc. and Advance Pharmaceutical Company Limited effective as of June 24, 2011 (Filed With SEC on September 21, 2012)

Employment Agreement between Boston Therapeutics, Inc. and Ken Tassey dated as of August 11, 2011 (Filed With SEC on September 21, 2012)

Certain portions of this exhibit, as indicated by [***] , have been omitted, pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of... (Filed With SEC on August 15, 2011)

EMPLOYMENT AGREEMENT (Filed With SEC on August 15, 2011)

BOSTON THERAPEUTICS, INC. SUBSCRIPTION AGREEMENT (Filed With SEC on June 22, 2011)

TECHNOLOGY ASSIGNMENT AGREEMENT (Filed With SEC on June 24, 2010)

AVANYX THERAPEUTICS, INC. 2010 STOCK PLAN (Filed With SEC on June 24, 2010)

PROMISSORY NOTE $78,820.28Made as of February 9, 2010 (Filed With SEC on June 24, 2010)

Boston Therapeutics, Inc. (105)